<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Jpn J Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Jpn. J. Cancer Res</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006a</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Japanese Journal of Cancer Research : Gann</journal-title></journal-title-group><issn pub-type="ppub">0910-5050</issn><issn pub-type="epub">1876-4673</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9247610</article-id><article-id pub-id-type="pmc">5921454</article-id><article-id pub-id-type="doi">10.1111/j.1349-7006.1997.tb00412.x</article-id><article-id pub-id-type="publisher-id">CAE517</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic Study of Carboplatin Given on a 5&#x02010;Day Intravenous Schedule</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author" corresp="yes"><name><surname>Ando</surname><given-names>Yuichi</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib id="cr2" contrib-type="author"><name><surname>Minami</surname><given-names>Hironobu</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib id="cr3" contrib-type="author"><name><surname>Saka</surname><given-names>Hideo</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr4" contrib-type="author"><name><surname>Ando</surname><given-names>Masahiko</given-names></name><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib id="cr5" contrib-type="author"><name><surname>Sugiura</surname><given-names>Seiji</given-names></name><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib id="cr6" contrib-type="author"><name><surname>Sakai</surname><given-names>Shuzo</given-names></name><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib id="cr7" contrib-type="author"><name><surname>Shimokata</surname><given-names>Kaoru</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib></contrib-group><aff id="a1"><label><sup>1</sup></label>First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai&#x02010;cho, Showa&#x02010;ku, Nagoya 466</aff><aff id="a2"><label><sup>2</sup></label>Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, 3&#x02010;35 Michishita, Nakamum&#x02010;ku, Nagoya 453</aff><author-notes><corresp id="correspondenceTo"><label>*</label>To whom all correspondence should be addressed at the First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai&#x02010;cho, Showa&#x02010;ku, Nagoya 466.</corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>1997</year></pub-date><volume>88</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/cas.1997.88.issue-5</issue-id><fpage>517</fpage><lpage>521</lpage><history>
(<italic>Received December 5, 1996/Accepted March 3, 1997</italic>)</history><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-88-517.pdf"/><abstract><p>We investigated whether carboplatin pharmacokinetics is altered when the drug is delivered daily over 5 days, compared to a single&#x02010;day infusion. Carboplatin was infused in 11 patients with lung cancer, who were randomly assigned to 2 groups. In the first group, the agent was administered on a conventional single&#x02010;day schedule in the first course and then on a 5&#x02010;day schedule in the second course. In the second group, the order was reversed (crossover design). The dose was calculated using Calvert's formula with 24 h creatinine clearance (Ccr, ml/min) as a substitute for glomerular filtration rate (GFR): carboplatin (mg) = AUC X (Ccr+25), where AUC denotes the area under the concentration versus time curve (mg ml<sup>&#x02013;1</sup> min). No difference of carboplatin clearance between the single&#x02010;day and 5&#x02010;day schedule was observed (94.8&#x000b1; 19.9 <italic>versus</italic> 96.1+29.9 ml/min, <italic>P</italic>=0.818, paired <italic>t</italic> test). The formula systematically overestimated the carboplatin clearance; the ratio of estimated clearance/ observed clearance ranged from 1.01 to 1.58 (median 1.28; 95% confidence interval, 1.18 to 1.39). We concluded that the individual dosing strategy based on renal function can be applied with a 5&#x02010;day schedule as well as a single&#x02010;day schedule. Carboplatin is overdosed when Ccr is substituted for GFR in Calvert's formula.</p></abstract><kwd-group><kwd id="k1">Carboplatin</kwd><kwd id="k2">Pharmacokinetics</kwd><kwd id="k3">Creatinine clearance</kwd><kwd id="k4">Lung cancer</kwd></kwd-group><counts><ref-count count="19"/><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 1997</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015</meta-value></custom-meta></custom-meta-group></article-meta></front><back><ref-list id="ss1"><title>REFERENCES</title><ref id="b1"><label>1</label><mixed-citation publication-type="journal" id="cit1">
)
<string-name><surname>Harland</surname>
,
<given-names>S.J.</given-names></string-name>
,
<string-name><surname>Newell</surname>
,
<given-names>D. R.</given-names></string-name>
,
<string-name><surname>Siddik</surname>
,
<given-names>Z. H.</given-names></string-name>
,
<string-name><surname>Chadwick</surname>
,
<given-names>R.</given-names></string-name><string-name><surname>Calvert</surname>
,
<given-names>A. H.</given-names></string-name>
and
<string-name><surname>Harrap</surname>
,
<given-names>K. R.</given-names></string-name><article-title>Pharmacokinetics of <italic>cis</italic>&#x02010;diammine&#x02010;l, l&#x02010;cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function</article-title>
.
<source>Cancer Res.</source>
,
<volume>44</volume>
,
<fpage>1693</fpage>
&#x02013;
<lpage>1697</lpage>
(
<year>1984</year>
).
<pub-id pub-id-type="pmid">6367971</pub-id></mixed-citation></ref><ref id="b2"><label>2</label><mixed-citation publication-type="journal" id="cit2">
)
<string-name><surname>Egorin</surname>
,
<given-names>M. J.</given-names></string-name>
,
<string-name><surname>van Echo</surname>
,
<given-names>D. A.</given-names></string-name>
,
<string-name><surname>Tipping</surname>
,
<given-names>S. J.</given-names></string-name>
,
<string-name><surname>Olman</surname>
,
<given-names>E. A.</given-names></string-name>
,
<string-name><surname>Whitacre</surname>
,
<given-names>M. Y.</given-names></string-name>
,
<string-name><surname>Thompson</surname>
,
<given-names>B. W.</given-names></string-name>
and
<string-name><surname>Aisner</surname>
,
<given-names>J.</given-names></string-name><article-title>Pharmacokinetic and dosage reduction of <italic>cis</italic>&#x02010;diammine&#x02010;(l, l&#x02010;cyclobutanedicarboxylato)platinum in patients with impaired renal function</article-title>
.
<source>Cancer Res.</source>
,
<volume>44</volume>
,
<fpage>5432</fpage>
&#x02013;
<lpage>5438</lpage>
(
<year>1984</year>
).
<pub-id pub-id-type="pmid">6386150</pub-id></mixed-citation></ref><ref id="b3"><label>3</label><mixed-citation publication-type="journal" id="cit3">
)
<string-name><surname>Calvert</surname>
,
<given-names>A. H.</given-names></string-name>
,
<string-name><surname>Newell</surname>
,
<given-names>D. R.</given-names></string-name>
,
<string-name><surname>Gumbrell</surname>
,
<given-names>L. A.</given-names></string-name>
,
<string-name><surname>O'Reilly</surname>
,
<given-names>S</given-names></string-name>
,
<string-name><surname>Burnell</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Boxall</surname>
,
<given-names>F. E</given-names></string-name>
,
<string-name><surname>Siddik</surname>
,
<given-names>Z. H</given-names></string-name>
,
<string-name><surname>Judson</surname>
,
<given-names>L R.</given-names></string-name>
,
<string-name><surname>Gore</surname>
,
<given-names>M. E.</given-names></string-name>
and
<string-name><surname>Wiltshaw</surname>
,
<given-names>E.</given-names></string-name><article-title>Carboplatin dosage: prospective evaluation of a simple formula based on renal function</article-title>
.
<source>J. Clin. Oncol</source>
,
<volume>1</volume>
,
<fpage>1748</fpage>
&#x02013;
<lpage>1756</lpage>
(
<year>1989</year>
).
</mixed-citation></ref><ref id="b4"><label>4</label><mixed-citation publication-type="journal" id="cit4">
)
<string-name><surname>Kyriazis</surname>
,
<given-names>A. P.</given-names></string-name>
,
<string-name><surname>Yagoda</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Kyriazis</surname>
,
<given-names>A. A.</given-names></string-name>
and
<string-name><surname>Fogh</surname>
,
<given-names>J.</given-names></string-name><article-title>Response of nude mouse&#x02010;grown human urothelial cancer to <italic>cis</italic>&#x02010;dianuninedichloroplatinum(II), diammine[l, l&#x02010;cy&#x02010;clobutanedicarboxylato(2&#x02010;)&#x02010;<italic>0,0&#x02032;</italic>&#x02010;platinum], and mitoguazone dihydrochloride</article-title>
.
<source>Cancer Res.</source>
,
<volume>45</volume>
,
<fpage>2012</fpage>
&#x02013;
<lpage>2015</lpage>
(
<year>1985</year>
).
<pub-id pub-id-type="pmid">3886128</pub-id></mixed-citation></ref><ref id="b5"><label>5</label><mixed-citation publication-type="journal" id="cit5">
)
<string-name><surname>Kyriazis</surname>
,
<given-names>A. P.</given-names></string-name>
,
<string-name><surname>Kyriazis</surname>
,
<given-names>A. A.</given-names></string-name>
,
<string-name><surname>Yagoda</surname>
,
<given-names>A.</given-names></string-name>
and
<string-name><surname>Fogh</surname>
,
<given-names>J.</given-names></string-name><article-title>Response of nude mouse&#x02010;grown adenocarcinomas of the human exocrine pancreas to <italic>cis</italic>&#x02010;diamminedichloroplati&#x02010;num(II), diammine[l, l&#x02010;cyclobutanedicarboxylato(2&#x02010;)&#x02010;O, <italic>O</italic>'&#x02010;platinum], and mitoguazone dihydrochloride</article-title>
.
<source>Cancer Res.</source>
,
<volume>45</volume>
,
<fpage>4354</fpage>
&#x02013;
<lpage>4359</lpage>
(
<year>1985</year>
).
<pub-id pub-id-type="pmid">3896479</pub-id></mixed-citation></ref><ref id="b6"><label>6</label><mixed-citation publication-type="journal" id="cit6">
)
<string-name><surname>van Echo</surname>
,
<given-names>D. A.</given-names></string-name>
,
<string-name><surname>Egorin</surname>
,
<given-names>M. J.</given-names></string-name>
,
<string-name><surname>Whitacre</surname>
,
<given-names>M. Y.</given-names></string-name>
,
<string-name><surname>Olman</surname>
,
<given-names>E. A.</given-names></string-name>
and
<string-name><surname>Aisner</surname>
,
<given-names>J.</given-names></string-name><article-title>Phase I clinical and pharmacologic trial of carboplatin daily for 5 days</article-title>
.
<source>Cancer Treat. Rep.</source>
,
<volume>68</volume>
,
<fpage>1103</fpage>
&#x02013;
<lpage>1114</lpage>
(
<year>1984</year>
).
<pub-id pub-id-type="pmid">6383605</pub-id></mixed-citation></ref><ref id="b7"><label>7</label><mixed-citation publication-type="journal" id="cit7">
)
<string-name><surname>Rozencweig</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Nicaise</surname>
,
<given-names>C.</given-names></string-name>
,
<string-name><surname>Beer</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Crespeigne</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>van Rijmenant</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Lenaz</surname>
,
<given-names>L.</given-names></string-name>
and
<string-name><surname>Kenis</surname>
,
<given-names>Y.</given-names></string-name><article-title>Phase I study of carboplatin given on a five&#x02010;day intravenous schedule</article-title>
.
<source>J. Clin. Oncol</source>
,
<volume>1</volume>
,
<fpage>621</fpage>
&#x02013;
<lpage>626</lpage>
(
<year>1983</year>
).
<pub-id pub-id-type="pmid">6366128</pub-id></mixed-citation></ref><ref id="b8"><label>8</label><mixed-citation publication-type="journal" id="cit8">
)
<string-name><surname>Daugaard</surname>
,
<given-names>G.</given-names></string-name>
,
<string-name><surname>Rossing</surname>
,
<given-names>N.</given-names></string-name>
and
<string-name><surname>R&#x000f8;rth</surname>
,
<given-names>M.</given-names></string-name><article-title>Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high&#x02010;dose</article-title>
.
<source>Cancer Chemother. Pharmacol.</source>
,
<volume>21</volume>
,
<fpage>163</fpage>
&#x02013;
<lpage>167</lpage>
(
<year>1988</year>
).
<pub-id pub-id-type="pmid">3280153</pub-id></mixed-citation></ref><ref id="b9"><label>9</label><mixed-citation publication-type="journal" id="cit9">
)
<string-name><surname>Mulder</surname>
,
<given-names>P. O. M</given-names></string-name>
,
<string-name><surname>de Vries</surname>
,
<given-names>E. G. E</given-names></string-name>
,
<string-name><surname>Uges</surname>
,
<given-names>D. R. A.</given-names></string-name>
,
<string-name><surname>Scaf</surname>
,
<given-names>A. H. J.</given-names></string-name>
,
<string-name><surname>Sleijfer</surname>
,
<given-names>D. T.</given-names></string-name>
and
<string-name><surname>Mulder</surname>
,
<given-names>N. H.</given-names></string-name><article-title>Pharmacokinetics of carboplatin at a dose of 750 mg m<sup>&#x02212;2</sup> divided over three consecutive days</article-title>
.
<source>Br, J. Cancer</source>
,
<volume>61</volume>
,
<fpage>460</fpage>
&#x02013;
<lpage>464</lpage>
(
<year>1990</year>
).
<pub-id pub-id-type="pmid">2183874</pub-id></mixed-citation></ref><ref id="b10"><label>10</label><mixed-citation publication-type="journal" id="cit10">
)
<string-name><surname>Lam</surname>
,
<given-names>F. C.</given-names></string-name>
,
<string-name><surname>Hung</surname>
,
<given-names>C. T.</given-names></string-name>
and
<string-name><surname>Perrier</surname>
,
<given-names>D. G.</given-names></string-name><article-title>Estimation of variance for harmonic mean half&#x02010;lives</article-title>
.
<source>J. Pharm. Sci.</source>
,
<volume>74</volume>
,
<fpage>229</fpage>
&#x02013;
<lpage>231</lpage>
(
<year>1985</year>
).
<pub-id pub-id-type="pmid">3989700</pub-id></mixed-citation></ref><ref id="b11"><label>11</label><mixed-citation publication-type="journal" id="cit11">
)
<string-name><surname>Hills</surname>
,
<given-names>M.</given-names></string-name>
and
<string-name><surname>Armitage</surname>
,
<given-names>P.</given-names></string-name><article-title>The two&#x02010;period cross&#x02010;over clinical trial</article-title>
.
<source>Br. J. Clin. Pharmacol.</source>
,
<volume>8</volume>
,
<fpage>7</fpage>
&#x02013;
<lpage>20</lpage>
(
<year>1979</year>
).
<pub-id pub-id-type="pmid">552299</pub-id></mixed-citation></ref><ref id="b12"><label>12</label><mixed-citation publication-type="journal" id="cit12">
)
<string-name><surname>Sheiner</surname>
,
<given-names>L. B.</given-names></string-name>
and
<string-name><surname>Seal</surname>
,
<given-names>S. L.</given-names></string-name><article-title>Some suggestions for measuring predictive performance</article-title>
.
<source>J. Phartnacokinet. Biopharm.</source>
,
<volume>9</volume>
,
<fpage>503</fpage>
&#x02013;
<lpage>512</lpage>
(
<year>1981</year>
).
</mixed-citation></ref><ref id="b13"><label>13</label><mixed-citation publication-type="book" id="cit13">
)
<string-name><surname>Armitage</surname>
,
<given-names>P.</given-names></string-name>
and
<string-name><surname>Berry</surname>
,
<given-names>G.</given-names></string-name><chapter-title>The size of statistical investigation</chapter-title>
.
<italic>In</italic>
&#x0201c;
<source>Statistical Methods in Medical Research</source>
,&#x0201d;
<edition>3rd Ed</edition>
,
pp.
<fpage>195</fpage>
&#x02013;
<lpage>206</lpage>
(
<year>1994</year>
).
<publisher-name>Blackwell Science Ltd.</publisher-name>
,
Oxford
.
</mixed-citation></ref><ref id="b14"><label>14</label><mixed-citation publication-type="journal" id="cit14">
)
<string-name><surname>van Warmerdam</surname>
,
<given-names>L. J. C.</given-names></string-name>
,
<string-name><surname>Rodenhuis</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>van Tellingen</surname>
,
<given-names>O.</given-names></string-name>
,
<string-name><surname>Maes</surname>
,
<given-names>R. A. A.</given-names></string-name>
and
<string-name><surname>Beijnen</surname>
,
<given-names>J. H.</given-names></string-name><article-title>Validation of a limited sampling model for carboplatin in a high&#x02010;dose chemotherapy combination</article-title>
.
<source>Cancer Chemother. Pharmacol.</source>
,
<volume>35</volume>
,
<fpage>179</fpage>
&#x02013;
<lpage>181</lpage>
(
<year>1994</year>
).
<pub-id pub-id-type="pmid">7987998</pub-id></mixed-citation></ref><ref id="b15"><label>15</label><mixed-citation publication-type="journal" id="cit15">
)
<string-name><surname>Reece</surname>
,
<given-names>P. A</given-names></string-name>
,
<string-name><surname>Bishop</surname>
,
<given-names>J. F.</given-names></string-name>
,
<string-name><surname>Olver</surname>
,
<given-names>I. N</given-names></string-name>
,
<string-name><surname>Stafford</surname>
,
<given-names>I.</given-names></string-name>
,
<string-name><surname>Hillcoat</surname>
,
<given-names>B. L.</given-names></string-name>
and
<string-name><surname>Morstyn</surname>
,
<given-names>G.</given-names></string-name><article-title>Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma</article-title>
.
<source>Cancer Chemother. Pharmacol.</source>
,
<volume>19</volume>
,
<fpage>326</fpage>
&#x02013;
<lpage>330</lpage>
(
<year>1987</year>
).
<pub-id pub-id-type="pmid">3036389</pub-id></mixed-citation></ref><ref id="b16"><label>16</label><mixed-citation publication-type="journal" id="cit16">
)
<string-name><surname>S&#x000f8;rensen</surname>
,
<given-names>B.T.</given-names></string-name>
,
<string-name><surname>Stromgren</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Jakobsen</surname>
,
<given-names>P.</given-names></string-name>
and
<string-name><surname>Jakobsen</surname>
,
<given-names>A.</given-names></string-name><article-title>A limited sampling method for estimation of the carboplatin area under the curve</article-title>
.
<source>Cancer Chemother. Pharmacol.</source>
,
<volume>31</volume>
,
<fpage>324</fpage>
&#x02013;
<lpage>327</lpage>
(
<year>1993</year>
).
<pub-id pub-id-type="pmid">8422698</pub-id></mixed-citation></ref><ref id="b17"><label>17</label><mixed-citation publication-type="journal" id="cit17">
)
<string-name><surname>S&#x000f8;rensen</surname>
,
<given-names>B.T</given-names></string-name>
,
<string-name><surname>Stromgren</surname>
,
<given-names>A</given-names></string-name>
,
<string-name><surname>Jakobsen</surname>
,
<given-names>P.</given-names></string-name>
and
<string-name><surname>Jakobsen</surname>
,
<given-names>A.</given-names></string-name><article-title>Is creatinine clearance a sufficient measurement for GFR in carboplatin dose calculation</article-title>
?
<source>Eur. J. Cancer</source>
,
<volume>29</volume>
,
<fpage>S110</fpage>
(
<year>1993</year>
).
</mixed-citation></ref><ref id="b18"><label>18</label><mixed-citation publication-type="journal" id="cit18">
)
<string-name><surname>Chatelut</surname>
,
<given-names>E.</given-names></string-name>
,
<string-name><surname>Chevreau</surname>
,
<given-names>C.</given-names></string-name>
,
<string-name><surname>Brunner</surname>
,
<given-names>V.</given-names></string-name>
,
<string-name><surname>Martinez</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Houin</surname>
,
<given-names>G.</given-names></string-name>
,
<string-name><surname>Bugat</surname>
,
<given-names>R.</given-names></string-name>
and
<string-name><surname>Canal</surname>
,
<given-names>P. A</given-names></string-name><article-title>pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer</article-title>
.
<source>Cancer Chemother. Pharmacol.</source>
,
<volume>35</volume>
,
<fpage>391</fpage>
&#x02013;
<lpage>396</lpage>
(
<year>1995</year>
).
<pub-id pub-id-type="pmid">7850920</pub-id></mixed-citation></ref><ref id="b19"><label>19</label><mixed-citation publication-type="journal" id="cit19">
)
<string-name><surname>van Warmerdam</surname>
,
<given-names>L. J. C.</given-names></string-name>
,
<string-name><surname>Rodenhuis</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>ten Bokkel Huinink</surname>
,
<given-names>W. W.</given-names></string-name>
,
<string-name><surname>Maes</surname>
,
<given-names>R. A. A.</given-names></string-name>
and
<string-name><surname>Beijnen</surname>
,
<given-names>J. H.</given-names></string-name><article-title>Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin</article-title>
.
<source>Cancer Chemother. Pharmacol.</source>
,
<volume>37</volume>
,
<fpage>266</fpage>
&#x02013;
<lpage>270</lpage>
(
<year>1996</year>
).
<pub-id pub-id-type="pmid">8529288</pub-id></mixed-citation></ref></ref-list></back></article>